Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.76 |
| ▸ | BCR | P11274 | 4/20 | 0.76 |
| ▸ | PRKCA | P17252 | 3/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.70 |
| ▸ | PLK1 | P53350 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.61 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CDK4 | P11802 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CCND1 | P24385 | 1/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513778 | 0.88 | CAMK2D (0.73) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL6254782 | 0.86 | ABL1 (1.00) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL5733933 | 0.86 | CAMK2D (0.71) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL5732902 | 0.85 | CAMK2D (0.77) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL2328157 | 0.85 | CAMK2D (0.70) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL5735831 | 0.84 | ABL1 (0.66) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL7468539 | 0.83 | ABL1 (0.71) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL7467324 | 0.83 | ABL1 (0.76) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL1789 | 0.83 | ABL1 (1.00) | ABL1BCRPRKCAPRKCDSRC | |
| SCHEMBL2321985 | 0.83 | CAMK2D (0.67) | ABL1BCRPRKCAPRKCDSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-0672042-B1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-5728708-A | ANTITUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| US-5705502-A | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885BCR 2315/4885PRKCA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.